Werner Poewe — International Movement Disorder Expert
Affiliation: Medical University of Innsbruck, Department of Neurology
Location: Innsbruck, Austria
Focus: Parkinson's disease, atypical parkinsonism (PSP, MSA, CBD), movement disorder clinical trials, international diagnostic criteria development
Overview
Werner Poewe, MD is a distinguished Austrian neurologist and Professor of Neurology at the [Medical University of Innsbruck](https://www.i-med.ac.at), widely recognized as one of the world's leading authorities on movement disorders. With over 600 peer-reviewed publications and more than 29,000 citations, his career has fundamentally shaped the understanding, diagnosis, and treatment of Parkinson's disease and atypical parkinsonian syndromes including Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Degeneration (CBD)[@lennon2024][@paluzzi2024].
Dr. Poewe has served as President of the [Movement Disorder Society (MDS)](https://www.movementdisorder.org), the leading international professional organization in the field, and has been instrumental in developing the international diagnostic criteria that define how PSP, MSA, and PD are diagnosed worldwide[@clinical2017][@msa2017].
Background and Training
...Werner Poewe — International Movement Disorder Expert
Affiliation: Medical University of Innsbruck, Department of Neurology
Location: Innsbruck, Austria
Focus: Parkinson's disease, atypical parkinsonism (PSP, MSA, CBD), movement disorder clinical trials, international diagnostic criteria development
Overview
Werner Poewe, MD is a distinguished Austrian neurologist and Professor of Neurology at the [Medical University of Innsbruck](https://www.i-med.ac.at), widely recognized as one of the world's leading authorities on movement disorders. With over 600 peer-reviewed publications and more than 29,000 citations, his career has fundamentally shaped the understanding, diagnosis, and treatment of Parkinson's disease and atypical parkinsonian syndromes including Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Degeneration (CBD)[@lennon2024][@paluzzi2024].
Dr. Poewe has served as President of the [Movement Disorder Society (MDS)](https://www.movementdisorder.org), the leading international professional organization in the field, and has been instrumental in developing the international diagnostic criteria that define how PSP, MSA, and PD are diagnosed worldwide[@clinical2017][@msa2017].
Background and Training
Dr. Poewe completed his medical training and neurology residency in Austria, with additional research training at international centers including University College London (UCL) and the University of Pennsylvania. He joined the faculty at Medical University of Innsbruck, where he established and led the movement disorders program that became one of Europe's premier centers for Parkinson's disease and atypical parkinsonism research and clinical care.
He served as Director of the Parkinson's Disease and Movement Disorders Center at Innsbruck, overseeing a comprehensive program integrating clinical care, clinical trials, neuroimaging research, and biomarker development.
Research Contributions
International Diagnostic Criteria Development
A cornerstone of Dr. Poewe's impact has been his leadership in establishing international consensus diagnostic criteria:
MDS Clinical Diagnostic Criteria for PSP (2017)
Dr. Poewe was a key contributor to the Movement Disorder Society criteria for PSP clinical diagnosis[@clinical2017], which:
- Established a four-level classification system (probable PSP, possible PSP, suggested PSP, and PSP/pathology)
- Incorporated core clinical features (ocular motor dysfunction, postural instability, akinesia, and frontal cognitive dysfunction)
- Defined variant PSP phenotypes (PSP-Parkinsonism, PSP-PAGF, PSP-PGS, PSP-CBS)
- Introduced support and exclusion features for each diagnostic level
Revised MDS Criteria for PSP (2023)
The 2023 revision incorporated emerging knowledge about PSP clinical heterogeneity[@hoglinger2023]:
- Expanded the phenotypic spectrum with 14 PSP variants now recognized
- Added early radiological markers (midbrain atrophy, "hummingbird sign")
- Incorporated fluid biomarkers (NfL, p-tau217) as supporting features
- Defined "laboratory-supported probable PSP" for biomarker-confirmed cases
Second Consensus Criteria for MSA (2017)
Dr. Poewe co-authored the second consensus criteria for MSA[@msa2017], which:
- Classified MSA into cerebellar (MSA-C) and parkinsonian (MSA-P) predominant subtypes
- Established first consensus autonomic feature criteria
- Defined imaging red flags supporting MSA diagnosis
Parkinson's Disease Natural History and Clinical Trials
Dr. Poewe has led or contributed to landmark PD studies:
Lancet Neurology Commission on Parkinson's Disease (2024)
As a lead author of the 2024 comprehensive commission[@lennon2024], Dr. Poewe synthesized the state of PD knowledge across:
- Epidemiology: Global PD prevalence estimates, risk factors, and demographic trends
- Disease mechanisms: Alpha-synuclein propagation, mitochondrial dysfunction, neuroinflammation
- Diagnostic criteria: Revised UK Brain Bank criteria, emerging prodromal markers
- Therapeutic strategies: Disease-modifying approaches, device-aided therapies, personalized medicine
Global Burden of Parkinson's Disease (2024)
Contributed to comprehensive epidemiological analysis[@bhatti2024] documenting:
- Global increase in PD prevalence from 2.5M (1990) to 6.1M (2019)
- Projected 12.4M PD cases by 2040
- Regional variation in prevalence and mortality
Multi-Ancestry GWAS of PD (2024)
Contributed to the largest PD genetic meta-analysis[@paluzzi2024]:
- 37 ancestry groups, 487,030 PD cases and 1.4M controls
- 92 independent genetic risk loci (71 novel)
- Polygenic risk scores validated for PD prediction
- Population-specific risk architectures affecting therapeutic development
Multiple System Atrophy
Dr. Poewe's work on MSA has been foundational[@wenning2013]:
- Natural history study: Prospective cohort of 200 MSA patients documented mean survival of 6.2 years from onset, with MSA-C showing shorter survival than MSA-P. Disease progression measured by Unified MSA Rating Scale (UMSARS) showed annual decline of 6.8 points
- Therapeutic advances review: Comprehensive 2015 analysis[@therapeutic2015] of symptomatic and disease-modifying approaches in MSA and PSP, establishing benchmarks for clinical trial placebo arm response rates
- Neuroimaging biomarkers: Contributions to developing MRI markers for MSA differential diagnosis from PD and PSP, including the "hot cross bun" sign and pontine hyperintensities
Atypical Parkinsonian Syndromes
Beyond MSA, Dr. Poewe has addressed the full spectrum of atypical parkinsonism:
- Automated tractography for PSP diagnosis: Research applying diffusion tensor imaging and probabilistic tractography to distinguish PSP variants from PD[@automated2020]
- Clinical trial design: Contributed to Phase 2 and 3 trial methodology for disease-modifying agents in PSP and MSA, including endpoint selection and enrichment strategies
- Phenomenology: Detailed clinical characterization distinguishing features of PSP, MSA, and CBD from idiopathic PD, including oculomotor findings, early falls, autonomic dysfunction, and response to levodopa
Long-Term Therapies in Movement Disorders
2024 Review of Innovative Therapy Long-Term Safety (2024)
Dr. Poewe's recent work[@poewe2024] evaluated:
- Long-term outcomes of device-aided therapies (DBS, continuous subcutaneous apomorphine infusion, LCIG)
- Disease-modifying therapy safety profiles at 5+ year follow-up
- Cumulative adverse event analysis across treatment modalities
Clinical Trials Leadership
Dr. Poewe has served as principal investigator or steering committee member for numerous trials in PD and atypical parkinsonism:
| Trial | Phase | Role | Therapeutic Area |
|-------|-------|------|-----------------|
| Various DBS studies | III | Site PI | Parkinson's disease |
| Levodopa-carbidopa intestinal gel | III | Investigator | Advanced PD |
| Apomorphine continuous infusion | III | Investigator | PD motor fluctuations |
| Neuroprotective agents in PSP | II/III | Steering committee | PSP |
| Disease-modifying agents in MSA | II | Investigator | MSA |
International Leadership
Dr. Poewe's professional service includes:
- President, Movement Disorder Society (MDS) — 2016-2018
- Founding member, MDS Study Group on PSP and Atypical Parkinsonisms
- Committee member, International Parkinson and Movement Disorders Society
- Advisor, European Academy of Neurology movement disorder working group
- Editorial board: Movement Disorders (Associate Editor), Lancet Neurology, Journal of Neural Transmission
Awards and Recognition
- Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases (American Academy of Neurology)
- Election to National Academy of Medicine (US)
- MDS Honorary Membership for contributions to the field
- European Academy of Neurology Award for Outstanding Achievement in Movement Disorders
- H-index >100 with over 29,000 citations
Institutional Context
The [Medical University of Innsbruck](https://www.i-med.ac.at) provides Dr. Poewe with:
- Major referral center for movement disorders in Central Europe
- Access to the Austrian Parkinson and Atypical Parkinsonism Registry
- Neuroimaging facilities (3T MRI, PET) for biomarker research
- Clinical trials infrastructure for Phase I-III studies
- Linkages to European Reference Networks for Rare Neurological Diseases
Cross-Links
- [Parkinson's Disease](/diseases/parkinsons-disease) — Primary disease focus
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) — Diagnostic criteria work
- [Multiple System Atrophy](/diseases/multiple-system-atrophy) — MSA research
- [Movement Disorder Society](/organizations/movement-disorder-society) — Professional organization
- [Medical University of Innsbruck](/institutions/medical-university-of-innsbruck) — Institution
- [Diagnostic Criteria](/diseases/progressive-supranuclear-palsy#diagnosis) — PSP diagnostic criteria
- [Clinical Trials in PSP](/mechanisms/psp-clinical-trials) — Trial methodology